Vanderbilt Ingram Cancer Center Archives
Cancer registries and sarcoma research
Sep. 13, 2022—The number of sarcoma research studies that use the two largest U.S. cancer registries is increasing, but over one-third of studies that asked the same research question reported conflicting findings.
Grant supports research to study gastric cancer origins
Sep. 1, 2022—Vanderbilt researchers have received $5 million in funding from a new initiative by the National Cancer Institute that aims to define how gastric and gastroesophageal junction adenocarcinomas form and evolve at the cellular level.
Chic Aweareness ovarian cancer fundraiser moves online
Sep. 1, 2022—Chic Awearness, a fundraiser for ovarian cancer research at Vanderbilt-Ingram Cancer Center (VICC), is an online event this year from now throughout September with an in-store shopping opportunity to close out the month called Chic Week.
Blood cancer progression
Aug. 29, 2022—Vanderbilt researchers used single-cell technologies to explore the accumulation of mutations during blood cancer progression, which could help identify strategies for preventing leukemia before it occurs.
New high-tech biobank safeguards critical specimens
Aug. 25, 2022—by Bill Snyder Vanderbilt University Medical Center has opened a state-of-the-art automated biobanking system that can store as many as 10 million biospecimens, including blood and body fluids, tissue, and genetic and protein material, at temperatures down to minus 80 degrees Celsius. The “BioStore” was purchased from its manufacturer, Massachusetts-based Azenta Life Sciences, with the...
V Foundation support
Aug. 25, 2022—Shane Jacobson, chief executive officer of the V Foundation for Cancer Research, on left, visited Vanderbilt-Ingram Cancer Center on Monday to meet with former and current recipients of funding from the foundation.
Abramson, Eng, Johnson named to new VICC roles
Aug. 18, 2022—Three physician researchers at Vanderbilt-Ingram Cancer Center are assuming additional leadership roles.
Trial for colorectal cancer drug reaches primary endpoint
Aug. 17, 2022—A new therapy for metastatic colorectal cancer that has been granted fast track designation by the U.S. Food and Drug Administration has met its primary endpoint of overall survival in a phase 3 clinical trial.
Cell-free breast cancer “biopsy”
Aug. 11, 2022—The circulating DNA that tumors release is a reliable metric of tumor genomics and can be used to monitor molecular changes in metastatic breast cancer.
Couple’s gift helps support immunotherapy research
Aug. 11, 2022—Luke and Susan Simons have endowed a new directorship that will support research so that more people can benefit from immunotherapies.
Female bladder cancer patients to benefit from new care support coordinator
Aug. 4, 2022—A philanthropic gift of a patient care coordinator designated to assist female bladder cancer patients in education, clinical decision-making, surveillance, support and even screening, is the first of its kind at Vanderbilt University Medical Center.
Targeted cancer drug during pregnancy
Aug. 2, 2022—The targeted cancer therapy alectinib was safe as a treatment for lung cancer during two pregnancies in a patient with non-small cell lung cancer, according to a case report from Vanderbilt physicians.
